Interferon alpha for the treatment of advanced renal cancer

Expert Opin Biol Ther. 2005 Jun;5(6):749-62. doi: 10.1517/14712598.5.6.749.

Abstract

This paper is an overview on the place of IFN-alpha in metastatic renal cell carcinoma (MRCC). After a presentation of MRCC and the mode of action of IFN-alpha, the results of studies including IFN-alpha alone or in combination with IL-2, chemotherapy and other biological modifiers are presented. Finally, new trends for new drugs, including antiangiogenic therapies, are discussed.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antimetabolites, Antineoplastic / therapeutic use
  • Carcinoma, Renal Cell / blood supply
  • Carcinoma, Renal Cell / surgery
  • Carcinoma, Renal Cell / therapy*
  • Combined Modality Therapy
  • Fluorouracil / therapeutic use
  • Humans
  • Interferon-alpha / therapeutic use*
  • Interleukin-2 / therapeutic use
  • Kidney Neoplasms / blood supply
  • Kidney Neoplasms / surgery
  • Kidney Neoplasms / therapy*
  • Neoplasm Metastasis
  • Neovascularization, Pathologic / therapy
  • Randomized Controlled Trials as Topic

Substances

  • Angiogenesis Inhibitors
  • Antimetabolites, Antineoplastic
  • Interferon-alpha
  • Interleukin-2
  • Fluorouracil